bemarituzumab   Click here for help

GtoPdb Ligand ID: 11278

Synonyms: FPA-144 | FPA144
Compound class: Antibody
Comment: Bemarituzumab (FPA144) is first-in-class anti-fibroblast growth factor receptor 2b (FGFR2b) chemotherapy antibody from Five Prime Therapeutics [3]. Amgen acquired Five Prime in 2021. Bemarituzumab is a humanized immunoglobulin G1 (IgG1) isotype antibody. It binds to FGFR2b and promotes ADCC via enhanced binding to FcγRIIIa. Around 30% of HER2-negative gastric cancers are FGFR2b positive and bemarituzumab is designed to target this cancer subtype that uses the FGF/FGFR pathway to promote transformation, proliferation and angiogenesis.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
References
1. Catenacci DV, Tesfaye A, Tejani M, Cheung E, Eisenberg P, Scott AJ, Eng C, Hnatyszyn J, Marina N, Powers J et al.. (2019)
Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design.
Future Oncol, 15 (18): 2073-2082. [PMID:31094225]
2. Catenacci DVT, Rasco D, Lee J, Rha SY, Lee KW, Bang YJ, Bendell J, Enzinger P, Marina N, Xiang H et al.. (2020)
Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma.
J Clin Oncol, 38 (21): 2418-2426. DOI: 10.1200/JCO.19.01834 [PMID:32167861]
3. Xiang H, Liu L, Gao Y, Ahene A, Macal M, Hsu AW, Dreiling L, Collins H. (2020)
Population pharmacokinetic analysis of phase 1 bemarituzumab data to support phase 2 gastroesophageal adenocarcinoma FIGHT trial.
Cancer Chemother Pharmacol, 86 (5): 595-606. [PMID:32965540]
4. (2020)
Bemarituzumab Is Active in FGFR2b-High Gastroesophageal Adenocarcinoma.
Cancer Discov, 10 (5): 638. [PMID:32220925]